Listed

Ernexa Therapeutics Inc.: Form 10-Q for the period ended Mar 31, 2012

Filed with the SEC on May 11, 2012 and accepted by EDGAR at May 11, 2012, 13:16 ET.

Share

Sections

The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2012-03-31. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Revenue3 months2012-01-01 to 2012-03-31$6.1mus-gaap:SalesRevenueNet
Selling, general and administrative3 months2012-01-01 to 2012-03-31$5.3mus-gaap:SellingGeneralAndAdministrativeExpense
Operating income3 months2012-01-01 to 2012-03-31−$997.0kus-gaap:OperatingIncomeLoss
Income tax3 months2012-01-01 to 2012-03-31$16.0kus-gaap:IncomeTaxExpenseBenefit
Net income3 months2012-01-01 to 2012-03-31−$1.0mus-gaap:NetIncomeLoss
Diluted EPS3 months2012-01-01 to 2012-03-31−$0.02us-gaap:EarningsPerShareBasicAndDiluted
Operating cash flow3 months2012-01-01 to 2012-03-31$255.0kus-gaap:NetCashProvidedByUsedInOperatingActivities
Capital expenditure3 months2012-01-01 to 2012-03-31$405.0kus-gaap:PaymentsToAcquirePropertyPlantAndEquipment
Cash and equivalentsAt period end2012-03-31$3.1mus-gaap:CashAndCashEquivalentsAtCarryingValue
Current assetsAt period end2012-03-31$4.4mus-gaap:AssetsCurrent
Total assetsAt period end2012-03-31$13.1mus-gaap:Assets
Current liabilitiesAt period end2012-03-31$3.9mus-gaap:LiabilitiesCurrent
Total liabilitiesAt period end2012-03-31$5.4mus-gaap:Liabilities
Shareholders' equityAt period end2012-03-31$7.7mus-gaap:StockholdersEquity

Source: SEC EDGAR, the filing index for accession 0001019687-12-001718. Last ingested by Listed: Nov 11, 2026, 02:49 ET. Listed shows no prices and gives no investment advice.